Intermittent Hypoxia Suppresses Adiponectin Secretion by Adipocytes

Magalang, Ulysses J.; Cruff, Jason; Rajappan, Ramkumar; Hunter, M. G.; Patel, Tushar; Marsh, Caleb; Raman, Subha V.; Parinandi, Narasimham L.

doi:10.1055/s-2008-1078738

Cited by 52 publications

(39 citation statements)

References 26 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levels of APN are inversely correlated with the proportion of body fat in adults. 3T3-L1 adipocytes exposed to intermittent hypoxia for 48 h had a significant decrease in the secretion of total and high-molecular-weight APN compared with control adipocytes maintained in 21% O 2 under identical conditions [102]. NAKAGAWA et al [103] demonstrated lower levels of circulating APN in patients with severe OSAS and sustained hypoxia reduced APN concentrations in C57BL/6J mice and 3T3-L1 adipocytes.…”

Section: In Vitro/in Vivo Studiesmentioning

confidence: 99%

Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation

Garvey

Taylor²,

McNicholas

2009

European Respiratory Journal

312

225

View full text Add to dashboard Cite

There is increasing evidence that intermittent hypoxia plays a role in the development of cardiovascular risk in obstructive sleep apnoea syndrome (OSAS) through the activation of inflammatory pathways. The development of translational models of intermittent hypoxia has allowed investigation of its role in the activation of inflammatory mechanisms and promotion of cardiovascular disease in OSAS. There are noticeable differences in the response to intermittent hypoxia between body tissues but the hypoxia-sensitive transcription factors hypoxia-inducible factor-1 and nuclear factor-kB appear to play a key role in mediating the inflammatory and cardiovascular consequences of OSAS. Expanding our understanding of these pathways, the cross-talk between them and the activation of inflammatory mechanisms by intermittent hypoxia in OSAS will provide new avenues of therapeutic opportunity for the disease.

show abstract

Section: In Vitro/in Vivo Studiesmentioning

confidence: 99%

Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation

Garvey

Taylor²,

McNicholas

2009

European Respiratory Journal

312

225

View full text Add to dashboard Cite

show abstract

“…It has been observed that sleep disruption and hypoxemia may produce alterations in the hypothalamic-pituitary-adrenal axis, which could be another factor in the causation of IR (41). Similarly, an increase in circulating free fatty acids (42) and a reduction in adiponectin secretion by adipocytes have been implicated (43).…”

Section: Original Articlementioning

confidence: 99%

Meta-analysis: Continuous Positive Airway Pressure Improves Insulin Resistance in Patients with Sleep Apnea without Diabetes

et al. 2013

View full text Add to dashboard Cite

Rationale: Obstructive sleep apnea (OSA) is an independent risk factor for the development of insulin resistance (IR). Treatment with continuous positive airway pressure (CPAP) for OSA has shown conflicting results on IR.Objectives: To conduct a meta-analysis of randomized controlled trials (RCTs) that have evaluated the effect of CPAP on a validated index of IR, the homeostasis model assessment of insulin resistance (HOMA-IR).Methods: PubMed and Embase were searched through August 10, 2012. Two independent reviewers screened citations to identify trials of the effect of CPAP on HOMA-IR. Data were extracted for postintervention HOMA-IR values. Measurements and Main Results:A total of five studies that enrolled 244 subjects (83% male) met the inclusion criteria. None of the subjects in the included studies had diabetes. The pooled estimate of the difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was 20.44 (95% confidence interval, 20.82 to 20.06; P = 0.02). The funnel plot does not suggest the presence of any publication bias. The I-squared index for the data on difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was 0.00 (P = 0.61). Conclusions:The pooled estimate of RCTs shows a favorable effect of CPAP on insulin resistance as measured by HOMA-IR in patients with OSA without diabetes. The effect size on HOMA-IR is modest, but not insignificant, when compared with the effects of thiazolidinedione in nondiabetic patients with metabolic syndrome. Further research and RCTs are warranted involving a larger number of patients and longer treatment periods to determine the beneficial effects of CPAP on IR.

show abstract

“…47 However, other studies on leptin levels and OSA have shown no effect independent of adiposity. 85 Insulin resistance is associated with low levels of adiponectin, 86 although the mechanism remains unclear; intermittent hypoxia has been proposed as a putative mechanism so adiponectin concentrations have been studied in OSA, with equivocal findings. 55,83 Sleep duration/fragmented sleep.…”

Section: Compromised Metabolism Insulin Resistance and Type 2 Diabetesmentioning

confidence: 99%

Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome

Seetho

Wilding

2014

Chron Respir Dis

View full text Add to dashboard Cite

Sleep-disordered breathing (SDB) encompasses a spectrum of conditions that can lead to altered sleep homeostasis. In particular, obstructive sleep apnoea (OSA) is the most common form of SDB and is associated with adverse cardiometabolic manifestations including hypertension, metabolic syndrome and type 2 diabetes, ultimately increasing the risk of cardiovascular disease. The pathophysiological basis of these associations may relate to repeated intermittent hypoxia and fragmented sleep episodes that characterize OSA which drive further mechanisms with adverse metabolic and cardiovascular consequences. The associations of OSA with type 2 diabetes and the metabolic syndrome have been described in studies ranging from epidemiological and observational studies to controlled trials investigating the effects of OSA therapy with continuous positive airway pressure (CPAP). In recent years, there have been rising prevalence rates of diabetes and obesity worldwide. Given the established links between SDB (in particular OSA) with both conditions, understanding the potential influence of OSA on the components of the metabolic syndrome and diabetes and the underlying mechanisms by which such interactions may contribute to metabolic dysregulation are important in order to effectively and holistically manage patients with SDB, type 2 diabetes or the metabolic syndrome. In this article, we review the literature describing the associations, the possible underlying pathophysiological mechanisms linking these conditions and the effects of interventions including CPAP treatment and weight loss.

show abstract

Intermittent Hypoxia Suppresses Adiponectin Secretion by Adipocytes

Cited by 52 publications

References 26 publications

Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation

Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation

Meta-analysis: Continuous Positive Airway Pressure Improves Insulin Resistance in Patients with Sleep Apnea without Diabetes

Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome

Contact Info

Product

Resources

About